Davis R M Inc. Sells 28,734 Shares of Pfizer Inc. (NYSE:PFE)

Davis R M Inc. trimmed its position in Pfizer Inc. (NYSE:PFE) by 54.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 24,323 shares of the biopharmaceutical company’s stock after selling 28,734 shares during the period. Davis R M Inc.’s holdings in Pfizer were worth $645,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Retirement Wealth Solutions LLC acquired a new stake in Pfizer in the fourth quarter worth about $26,000. Rialto Wealth Management LLC bought a new position in shares of Pfizer in the 4th quarter valued at about $26,000. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Pfizer during the fourth quarter worth approximately $28,000. Gladius Capital Management LP lifted its holdings in Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 38,015 shares during the period. Finally, Noble Wealth Management PBC bought a new position in Pfizer in the fourth quarter valued at approximately $31,000. 68.36% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the firm’s stock in a transaction dated Thursday, February 13th. The stock was bought at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.06% of the company’s stock.

Pfizer Stock Performance

Shares of Pfizer stock opened at $26.00 on Wednesday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a market cap of $147.33 billion, a price-to-earnings ratio of 18.44, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61. The stock’s 50-day moving average is $26.29 and its 200-day moving average is $27.19. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.10 EPS. Equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, March 7th. Investors of record on Friday, January 24th were given a $0.43 dividend. The ex-dividend date was Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.62%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is 121.99%.

Analyst Upgrades and Downgrades

PFE has been the subject of several recent research reports. Truist Financial dropped their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Citigroup cut their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 28th. Bank of America restated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. Finally, Guggenheim restated a “buy” rating and set a $33.00 price objective on shares of Pfizer in a report on Monday, February 10th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and a consensus target price of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.